Le syndrome de la lipodystrophie - Gouvernement du Québec

104. DRECHSLER H. et POWERLY, W.G. Switching effective antiretroviral therapy -
A Review, Clinical Infectious Diseases, vol. 35, 15 novembre 2002, p. 1219-1230.
105. MARTINEZ, E. et autres. « Substitution of nevirapine, efavirenz or abacavir for
protease inhibitors in patients with HIV infections», N Engl. J. Med, vol. 349,
n o 11, 11 septembre 2003, p. 1036-1046.
106. ROZENBAUM, W. et autres. Metabolic and clinical evaluation of lipodystrophy
48 weeks after switching from 2 NRTI/PI to 2 NRTI/abacavir, (French substudy,
CNA 30017) 2 nd International Workshop on Adverse Drug Reactions and
Lipodystrophy in HIV, 13-15 septembre 2000,Toronto, abrégé P89.
107. LAFEUILLADE, A. et autres « Comparison of metabolic abnormalities and
clinical lipodystrophy 48 weeks after switching from HAART to trizivir versus
continued HAART: The trizal study », HIV Clin Trials, vol. 4, n o 1, janvier-février
2003, p. 37-43.
108. CARR, A. et autres. « HIV protease inhibitor substitution in patients with
lipodystrophy: A randomized, controlled, open-label, multicentre study »,
AIDS, vol. 15, n o 14, septembre 2001, p. 1811-1822.
109. JOHN, M. et autres. « A randomised, controlled, 48 week study of switching
stavudine and/or protease inhibitors to combivir/abacavir to prevent or
reverse lipoatrophy in HIV-infected patients », JAIDS, vol. 33, 1 er mai 2003,
p. 29-33.
110. CARR, A. et autres. « Abacavir substitution for nucleoside analogs in patients
with HIV lipoatrophy. A randomized trial », JAMA, vol. 288, n o 2, 10 juillet
2002, p. 207-215.
111. MARTIN, A. et autres. « Long-term changes in lipodystrophy after switching
from thymidine analogues to abacavir », 5 th International Workshop on
Adverse Drug Reactions and Lipodystrophy in HIV, 8-11 juillet 2003, Paris,
abrégé 16.
112. HERNANDEZ, J. et autres. « Improvement in lipoatrophy associated with highly
active antiretroviral therapy in human immunodeficiency virus-infected
patients switched from stavudine to abacavir or zidovudine: The results of
the TARHEEL study », Clinical Infectious Diseases, vol. 38, n o 2, janvier 2004,
p. 263-270.
113. SAINT-MARC, T. et autres. Reversibility of peripheral fat wasting on stopping
stavudine therapy, 7 th Conference on Retroviruses and Opportunistic
Infections, 30 janvier-2 février 2000, San Francisco, abrégé 52.
114. WANKE,C.et autres.« Recombinant human growth hormone improves the fat
redistribution syndrome in patients with HIV », AIDS, vol.13, n o 15, 22 octobre
1999, p. 2099-2103.
115. ENGELSON, E.S. et autres. « Effect of recombinant human growth hormone
in the treatment of visceral fat accumulation in HIV infection », AIDS, vol. 30,
n o 4, 1 er août 2002, p. 379-391.
116. TORRES, R. Long-term follow-up of patients with HARS receiving rh-Gh:
Another dilemma of early versus delayed intervention?, XIII e International AIDS
Conference, 9-14 juillet 2000, Durban, abrégé WePeB4234.
117. LO, J. C. et autres. « The effect of recombinant human growth hormone on
body composition and glucose metabolism in HIV-infected patients with
fat accumulation », Journal of Clinical Endocrinology and Metabolism, vol. 86,
n o 8, août 2001, p. 3480-3487.
118. KOTLER, D. et autres. Growth hormone significantly reduces visceral adipose
tissue (VAT) accumulation and non-HDL cholesterol, XIV e International AIDS
Conference, 7-12 juillet 2002, Barcelone, abrégé LbOr18.
119. DIETERICH, D. et autres. Incidence of body habitus changes in a cohort of 725
HIV-infected patients, 6 th Conference on Retroviruses and Opportunistic
Infections, 31 janvier-4 février 1999, Chicago, abrégé 674.
120. HADIGAN, C. et autres. « Fasting hyperinsulinemia in HIV-infected men:
Relationship to body composition, gonadal function and protease inhibitor
use », Journal of Clinical Endocrinology and Metabolism, vol. 85, n o 1, 2000,
p. 35-41.
121. VISNEGARWALA, F. et M.R. MALDONADO. « Use of PPAR-c modulator
rosiglitazone in normoglycemic patients with HIV lipodystrophy syndrome »,
Antiviral Therapy, vol. 6, n o 4, 2001, p. 82.
122. HADIGAN, C. et autres. A randomised double-blind placebo-controlled study
of rosiglitazone for patients with lipodystrophy, 2 nd International AIDS
Conference, 14 juillet 2003, Paris, abrégé 50.
123. CALMY, A. et autres. « Glitazones in lipodystrophy syndrome induced by
HAART », AIDS, vol. 17, n o 5, 28 mars 2003, p. 770-772.
124. SUTINEN, J. et autres. « Rosiglitazone in the treatment of HAART-associated
lipodystrophy: A randomized, double-blind, placebo-controlled study »,
Antiviral Therapy, vol. 8, n o 3, juin 2003, p. 199-207.
125. CARR, A. et autres. « No effect of rosiglitazone for treatment of HIV-1
lipoatrophy: Randomised, double-blind, placebo-controlled trial », Lancet,
vol. 363, n o 9407, 7 février 2004, p. 429-438.
126. SAINT-MARC,T. Effects of metformin on insuline resistance and central adiposity
in patients receiving effective protease inhibitor therapy, 6 th Conference on
Retroviruses and Opportunistic Infections, 31 janvier-4 février 1999, Chicago,
abrégé 672.
127. MARTINEZ, E. et autres. « Effects of metformin or gemfibrozil on the
lipodystrophyof HIV-infected patients receiving protease inhibitors »,
Antiviral Therapy, vol. 8, n o 5, octobre 2003, p. 403-410.
128. HADIGAN, C. et autres. « Sustained benefits of metformin therapy in HIV
lipodystrophy », Antiviral Therapy,vol.6,n o 4, 2001, p. 48.
129. MAUSS, S. et G. SCHMUTZ. Lack of effect of L-Carnitine on HIV-associated
Lipodystrophy, 40 nd Interscience Conference on Antimicrobial Agents and
Chemotherapy, 17-20 septembre 2000, Toronto, abrégé 1291.
130. WOLFORT, F.G. et autres. « Suction-assisted lipectomy for lipodystrophy syndromes
attributed to HIV-protease inhibitor use », Plastic and Recontructive
Surgery, vol. 104, n o 6, novembre 1999, p. 1814-1820.
131. CHASTAIN, M.A. et autres. « HIV lipodystrophy: Review of the syndrome
and report of a case treated with liposuction », Dermatol Surg, vol. 27, n o 5,
mai 2001, p. 497-500.
132. PILIERO, P.J. et autres. « Use of ultrasonography-assisted liposuction for
the treatment of HIV-associated enlargement of the dorsocervical fat pad »,
Clinical Infectious Diseases, vol. 37, n o 15, novembre 2003, p. 1374-1377.
133. PONCE-DE LEON, S. et autres. « Liposuccion for protease inhibitor associated
lipodystrophy », Lancet, vol. 353, 1999, p. 1244.
134. LAFAURIE, M. et autres. Treatment of HIV-associated lipoatrophy of the face
with intradermal injections of polylactic acid, 9 th Conference on Retroviruses
and Opportunistic Infections, 24-28 février 2002, Seatle, abrégé 704-T.
135. VALANTIN, M.A. et autres. Polylactic acid implants in the correction of facial
lipoatrophy in HIV-infected patients, 10 th Conference on Retroviruses and
Opportunistic Infections, 10-14 février 2003, Boston, abrégé 719.
136. LEVAN, P. et autres. « Correction of facial lipoatrophy in HIV-infected patients
on highly active antiretroviral therapy by injection of autologous fatty
tissue », AIDS, vol. 16, n o 14, 2002, p. 1985-1870.
137. GUARALDI, G. et autres. Autologous fat transfer for treating facial wasting
in HIV fat redistribution syndrome, 10 th Conference on Retroviruses and
Opportunistic Infections, 10-14 férier 2003, Boston, abrégé 722.
138. STRAUCH, B. et autres. « Treatment of HIV-associated lipodystrophy with
dermafat graft transfer to the malar area », Plastic and Reconstructive Surgery,
vol. 113, n o 1, janvier 2004, p. 363-370.
31